A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn’t live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
